ReviewBrain sciences2021
Epidemiology of Anthropometric Factors in Glioblastoma Multiforme-Literature Review.
Review in Brain sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The HALLMOUNT Score: Development of a Novel Multidimensional Prognostic Model for Solid Tumors, with Initial Clinical Application in Grade 4 Adult-Type Diffuse Gliomas.Medicina (Kaunas, Lithuania) · 2025Article
- Molecular characterization of macrophage-related prognostic factors in glioblastoma revealed by combined analysis on single-cell and bulk transcriptome data.Discover oncology · 2025Article
- Extracellular vesicles as delivery vehicles and therapeutic agents for glioblastoma treatment: A systematic review of in vitro and in vivo preclinical studies.Asian journal of pharmaceutical sciences · 2025Review
- Anticancer Activity of Melittin-Containing Bee Venom Fraction Against Glioblastoma Cells In Vitro.International journal of molecular sciences · 2025Article
- Targeting LC3B/MCL-1 expression by Protodioscin induces autophagy and apoptosis in human glioblastoma cellsInternational journal of medical sciences · 2025Article
- New insights into targeted therapy of glioblastoma using smart nanoparticles.Cancer cell international · 2024Review
- Risk factors for glioblastoma in adults in Japan: an exploratory cohort study based on the Shizuoka Kokuho Database, the Shizuoka study.Journal of neuro-oncology · 2024Article
- Effects of HSV-G47Δ Oncolytic Virus on Telomerase and Telomere Length Alterations in Glioblastoma Multiforme Cancer Stem Cells Under Hypoxia and Normoxia Conditions.Current cancer drug targets · 2024Article
- Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM).Cancers · 2023Review
- Androgen Receptor Expression in the Various Regions of Resected Glioblastoma Multiforme Tumors and in an In Vitro Model.International journal of molecular sciences · 2022Article
- Childhood Obesity: A Potential Key Factor in the Development of Glioblastoma Multiforme.Life (Basel, Switzerland) · 2022Review
- CCL18 Expression Is Higher in a Glioblastoma Multiforme Tumor than in the Peritumoral Area and Causes the Migration of Tumor Cells Sensitized by Hypoxia.International journal of molecular sciences · 2022Article
- Allopregnanolone Promotes Migration and Invasion of Human Glioblastoma Cells through the Protein Tyrosine Kinase c-Src Activation.International journal of molecular sciences · 2022Article
- Comprehensive Analysis of the Brain-Expressed X-Link Protein Family in Glioblastoma Multiforme.Frontiers in oncology · 2022Article
- The Multifaceted Role of Extracellular Vesicles in Glioblastoma: microRNA Nanocarriers for Disease Progression and Gene Therapy.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although glioblastoma multiforme (GBM) is a widely researched cancer of the central nervous system, we still do not know its full pathophysiological mechanism and we still lack effective treatment methods as the current combination of surgery, radiotherapy, and chemotherapy does not bring about satisfactory results. The median survival time for GBM patients is only about 15 months. In this paper, we present the epidemiology of central nervous system (CNS) tumors and review the epidemiological data on GBM regarding gender, age, weight, height, and tumor location. The data indicate the possible influence of some anthropometric factors on the occurrence of GBM, especially in those who are male, elderly, overweight, and/or are taller. However, this review of single and small-size epidemiological studies should not be treated as definitive due to differences in the survey methods used. Detailed epidemiological registers could help identify the main at-risk groups which could then be used as homogenous study groups in research worldwide. Such research, with less distortion from various factors, could help identify the pathomechanisms that lead to the development of GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.